[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemodialysis-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemodialysis-patients":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,78,106,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642829","comparison-of-tunneled-cuffed-dialysis-catheters-versus-arteriovenous-fistulae-in-elderly-or-multimorbid-patients-100642829",false,"NCT07649083","Comparison of Tunneled Cuffed Dialysis Catheters Versus Arteriovenous Fistulae in Elderly or Multimorbid Patients","Inclusion Criteria:\n\n* Aged ≥60 years or \\\u003C60 years with a CCI Score \\>6\n* Patients with CKD G5 A1-3 with indication for hemodialysis\n* Stable clinical condition\n* Eligibility for both arteriovenous fistula on the upper extremities and TCC\n* Availability for follow-up\n* Written informed consent\n\nExclusion Criteria:\n\n* Uncontrolled infection and\u002For CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl) at screening\n* Poor overall health or malignancy not in remission at screening\n* Major surgery within 12 weeks before screening\n* Pre-existent vascular access\n* Patient not eligible for any one of the vascular access options\n* Endovascular arteriovenous fistula","ALL","18 Years","99 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients are randomly assigned to a study group. Depending on the study group, either an arteriovenous fistula or tunneled cuffed catheter (TCC) will be implanted, followed by continuous evaluation of the patients during the first year after initiating the vascular access. The evaluation includes statistical evaluation of all events, including loss of access, thrombosis, infection, loss of patency, increase in co-morbidities, e.g. congestive heart failure as well as quality of life. The implantation of the TCC is a standard procedure and it will be used only in accordance with the approved instructions of use on subjects who have signed an informed consent form. The surgery is a standard operation and it will be performed by specialized surgeons on subjects who have signed an informed consent form (No grafts will be used; implantation of a standard TCC, used at the Department of Nephrology). Both, an arteriovenous fistula or a TCC, will be used for routine chronic haemodialysis",[26,27,28,29,30],"End Stage Renal Failure, Hemodialysis","Vascular Access","Fistulas Arteriovenous","Haemodialysis Complication","Haemodialysis Patients","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Medical University of Vienna","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100637138","phase-2-vaccination-response-modulation-with-a-targeted-rapamycin-protocol-study-100637138","NCT07587801","Vaccination Response Modulation With a Targeted Rapamycin Protocol Study","Vaccination Response Modulation With a Targeted Rapamycin Protocol (VON TRAPP) Study","VON TRAPP","Inclusion Criteria:\n\n* End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy\n* Aged \\>60 years\n\nExclusion Criteria:\n\n* Aged \\\u003C60 years\n* Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)\n* Recent infection (\\\u003C6 months) with proven Influenza A, Influenza B, or RSV\n* Current use of immunosuppressive medications, including:\n\n  * Oral steroid at a dose equivalent of 5 mg\u002Fday prednisolone or greater\n  * Mycophenolate mofetil\n  * Azathioprine\n  * Calcineurin inhibitors\n  * mTOR inhibitors\n* Recent use of intravenous immunosuppressive medications (\\\u003C6 months), including:\n\n  * T-cell depleting agents (e.g. anti-thymocyte globulin)\n  * B-cell depleting agents (e.g. rituximab)\n  * Cyclophosphamide\n* Has a history of problems with side-effects associated with sirolimus use including\n\n  * Angioedema\n  * Active\u002Frecent opportunistic infection\n  * Current or prior interstitial lung disease, non-infectious pneumonitis, organising pneumonia, or pulmonary fibrosis\n  * Clinically significant pleural effusion or pericardial effusion\n  * Active non-healing wounds, chronic skin ulcers, or planned major surgery\u002Fprocedures\n  * Current malignancy or recent malignancy with high recurrence risk\n  * Severe or uncontrolled hyperlipidaemia\n  * History of rhabdomyolysis\n  * Severe hepatic impairment\n* Ongoing use of strong CYP3A4\u002FP-gp inhibitors or inducers including\n\n  * Inhibitors: Ketoconazole, Voriconazole, Itraconazole, Telithromycin, Clarithromycin\n  * Inducers: Rifampicin, Rifabutin\n* Unable or unwilling to provide informed consent to participate in the trial\n* Known allergy to or intolerance of sirolimus (rapamycin) or the contents of the influenza or RSV vaccine","60 Years",{"count":53,"type":20},60,[55],"PHASE2","This study will investigate dialysis recipients' responses to important vaccines.\n\nResearch suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.",[58,30,59],"Vaccine Immune Response","Older Adults",[61,62,63,64,65,66],"influenza","RSV","vaccine","haemodialysis","older adults","immunosenescence","2026-05-11",{"date":69,"type":35},"2026-05-14",{"date":71,"type":20},"2026-05",{"date":73,"type":20},"2026-07",{"name":75,"class":76},"Central Adelaide Local Health Network Incorporated","OTHER_GOV",3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100636574","pulsatile-flushing-technique-in-reducing-blockage-of-t-cvad-for-haemodialysis-patients-100636574","NCT07567456","Pulsatile Flushing Technique in Reducing Blockage of T-CVAD for Haemodialysis Patients","Exploring the Effectiveness of Pulsatile Flushing Technique in Reducing Blockage of the Tunnelled Central Venous Access Device Among Haemodialysis Patients in Multiple Renal Centres in Hong Kong: A Cluster Non-Randomised Controlled Trial Study","Non-RCT HD","Inclusion Criteria:\n\n* Patients undergoing HD treatment with Tunnelled Central Venous Access Device (T-CVAD) in the above collaborators under the Hospital Authority\n* Able to understand spoken and written Chinese or English\n\nExclusion Criteria:\n\n* Patients with Non-Tunnelled Central Venous Access Device (NT-CVAD)\n* Temporary dysfunction (e.g., kicking of the catheter) resolved with repositioning\n* Confirmed case of fibrin sheath occlusion which can only be resolved through surgical intervention\n* Non-thrombotic occlusion due to mechanical causes (e.g., catheter malposition)\n* Patient declined or incompetent to provide written informed consent.",{"count":87,"type":20},591,[23],"This study investigates the effectiveness of pulsatile flushing techniques in reducing blockage in Tunnelled Central Venous Access Device (T-CVAD) among patients undergoing haemodialysis (HD) treatment at multiple renal centres within the Hospital Authority (HA) in Hong Kong. With limitation in single service protocol for each cluster of renal units, it is designed as a prospective, parallel, cluster non-randomised controlled trial involving 591 patients from 14 renal units. In order to identify the most effective flushing technique for T-CVAD maintenance, survival analysis on clinical effectiveness, in terms time-to-event blockage of the T-CVAD, among three trial arms: 1) Intervention Group A (IG-A) using pulsatile flushing technique with 0.4 second pause time interval; 2) Intervention Group B (IG-B) using pulsatile flushing technique with 1 second pause time interval; 3) Control Group (Con) using standard bolus flushing technique. The findings facilitate development of best practice for T-CVAD maintenance, optimise T-CVAD maintenance protocols, and ultimately improve patient outcomes. This groundbreaking study is expected to signify substantial progression in the nursing management of HD and T-CVAD.",[30,91,92],"Blockage of Tunnelled Central Venous Access Device","Pulsatile Flushing Technique",[94,95,92],"HD","T-CVAD","RECRUITING","2026-05-05",{"date":67,"type":35},{"date":100,"type":35},"2026-02-02",{"date":102,"type":20},"2027-12",{"name":104,"class":42},"Queen Elizabeth Hospital, Hong Kong",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":105},"100588233","laughter-yoga-intervention-in-patients-on-haemodialysis-100588233","NCT06938737","Laughter Yoga Intervention in Patients on Haemodialysis","Effects of Laughter Yoga on Happiness, Mental Well-being and Blood Pressure in Hemodialysis Patients: A Randomized Controlled Trial","laughter yoga","Inclusion Criteria:\n\n1. Those receiving hemodialysis treatment at Fethiye Can Dialysis Center with a diagnosis of CKD\n2. 18 years of age and older\n3. Ability to read and understand\n4. Those receiving hemodialysis treatment for six months or longer\n5. Interdialytic fluid intake not more than 5% of total weight\n6. Able to communicate in Turkish\n7. No hearing or vision loss\n8. Patients who volunteer to participate in the study\n\nExclusion Criteria:\n\n1. Those with interdialytic fluid intake greater than 5% of total weight\n2. Those with respiratory system diseases that negatively affect the practice of laughter yoga (COPD, asthma, bronchiectasis, lung infections, etc.)\n3. Those with hearing and vision loss\n4. Those who want to leave the study despite completing the survey questions appropriately\n5. Those who do not agree to participate in the study\n6. Those aged 18 and under\n7. Those who start treatment at another dialysis center\n8. Those who change their renal replacement therapy type -",{"count":115,"type":20},72,[23],"This study was planned as a randomized controlled experimental type and pre-test-post-test design in order to examine the effects of laughter yoga applied to hemodialysis patients on the happiness and mental well-being levels of the patients and on blood pressure.\n\nThe universe of the study will be patients receiving hemodialysis treatment at Fethiye Özel Can Dialysis Center (N=184) and the sample will be a total of 72 patients, consisting of the experimental group (n=36) and the control group (n=36).\n\nAfter obtaining the permission of the ethics committee and institution, the data will be collected face to face by the researchers before and after the laughter yoga to be applied to hemodialysis patients receiving treatment at Fethiye Özel Can Dialysis Center and who agreed to participate in the study. In the collection of data; Introductory Information Form (TBF), Warwick-Edinburgh Mentai Well-Being Scale (WEMİOÖ), Oxford Happiness Scale (OMÖ) and blood pressure measurements of the patients will be used. IBM SPSS 25.0 package program will be used to evaluate the data.",[30,119],"Laughter Yoga",[121,112,122,123,124],"Haemodialysis","Happiness","Mental Well-being","blood pressure","2025-04-14",{"date":127,"type":35},"2025-04-22",{"date":129,"type":20},"2025-04-28",{"date":131,"type":20},"2025-06-20",{"name":133,"class":42},"Muğla Sıtkı Koçman University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100554559","studying-thyroid-function-of-haemodialysis-patients-in-upper-egypt-two-centers-study-100554559","NCT06500663","Studying Thyroid Function of Haemodialysis Patients in Upper Egypt (Two Centers Study).","Inclusion Criteria:\n\n1. Patients who have been on hemodialysis for at least 6 months.\n2. Patients aged between 18 and 75 years\n3. Patients without overt hyper\u002Fhypothyroidism or thyroid hormone supplementation (for examining endogenous thyroid function).\n\nExclusion Criteria:\n\n\\- 4. Patients with a history of thyroid disease or thyroid surgery. 5. Patients currently on medications known to affect thyroid function (e.g., amiodarone, lithium).\n\n6\\. Pregnant or breastfeeding women. 7. Patients with other serious illnesses (e.g., cancer, severe heart disease) that could affect thyroid function or the ability to participate in the study 8. Patients receiving thyroid hormone supplementation","75 Years",{"count":142,"type":20},160,"OBSERVATIONAL","1. The study aims to investigate the prevalence of thyroid dysfunction in haemodialysis patients and study the association of thyroid hormone concentration with health status of those patients\n2. Study the effects of frequent haemodialysis on thyroid function",[30],"2024-07-08",{"date":148,"type":35},"2024-07-15",{"date":150,"type":20},"2024-08-01",{"date":152,"type":20},"2026-12-30",{"name":154,"class":42},"Sahar Ezeldeen Hussein Ali"]